In this episode, David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, provide expert insights on practice-changing data and other new findings presented at SGO 2023 in endometrial, cervical, and ovarian cancers, including:NRG GY018: randomized phase III study evaluating standard of care of carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with endometrial cancerENGOT-EN6/GOG-3031/RUBY: randomized, placebo-controlled phase III study of dostarlimab plus standard-of-care chemotherapy in primary advanced or recurrent endometrial cancerPhase I NRG-GY017 study of priming-dose atezolizumab before or concurrently with chemoradiotherapy in locally advanced high-risk cervical cancerRandomized phase II study of chemoradiation plus pembrolizumab immunotherapy in locally advanced cervical cancerGOG 3026: phase II trial of letrozole plus ribociclib in women with recurrent low-grade serous ovarian cancerPresenters:David Scott Miller, MD, FACOG, FACSAmy and Vernon E. Faulconer Distinguished Chair in Medical ScienceDirector and Dallas Foundation Chair in Gynecologic OncologyProfessor of Obstetrics & GynecologyFred F. Florence Bioinformation CenterUniversity of Texas Southwestern Medical CenterMedical Director of Gynecologic Oncology Chair, Cancer CommitteeParkland Health & Hospital SystemDallas, TexasLinda Duska, MD, MPHGynecologic OncologistDepartment of OB GYN/Gynecologic OncologyUniversity of Virginia School of MedicineCharlottesville, VirginiaContent supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure Inc., and Seagen Inc.Link to full program: bit.ly/424E3Uq

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related